Gavrilina P D, Gamidov A A, Baum O I, Bolshunov A V, Khomchik O V, Sobol E N
I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia.
Research Institute of Eye Diseases, Moscow, Russia.
Vestn Oftalmol. 2020;136(6):113-120. doi: 10.17116/oftalma2020136061113.
Nowadays glaucoma is one of the leading causes of irreversible blindness worldwide. The main goal in preservation of vision in glaucoma patients is reducing intraocular pressure (IOP), which is considered the main controlled risk factor for progression of glaucomatous optic neuropathy. The article discusses the effectiveness and safety of various transscleral laser technologies in the treatment of glaucoma. Modern transscleral laser technologies that affect the uveoscleral drainage and scleral hydro-permeability are less traumatic and more gentle making them promising in the treatment of patients with early stages of glaucoma, and not only in terminal glaucoma with pain syndrome resistant to conventional treatment ("last resort surgery").
如今,青光眼是全球不可逆性失明的主要原因之一。青光眼患者视力保护的主要目标是降低眼压(IOP),眼压被认为是青光眼性视神经病变进展的主要可控风险因素。本文讨论了各种经巩膜激光技术治疗青光眼的有效性和安全性。影响葡萄膜巩膜引流和巩膜水渗透性的现代经巩膜激光技术创伤较小且更为温和,这使其在青光眼早期患者的治疗中具有前景,而不仅仅适用于对传统治疗(“最后手段手术”)有疼痛综合征的终末期青光眼。